Anika Therapeutics (ANIK) Finished Goods (2011 - 2018)

Anika Therapeutics (ANIK) has reported Finished Goods for 8 consecutive years, with $4.6 million the latest figure, recorded in Q3 2018.

• On a quarterly basis, Finished Goods fell 20.31% year-over-year to $4.6 million in Q3 2018; TTM through Sep 2018 was $4.6 million, a 20.31% decrease from a year earlier, with the FY2017 full-year figure at $4.7 million, up 3.02% from the prior year.
• Finished Goods was $4.6 million for Q3 2018 at Anika Therapeutics, down from $5.2 million in the prior quarter.
• Over five years, Finished Goods peaked at $6.8 million in Q1 2018 and troughed at $3.1 million in Q1 2015.
• A 5-year average of $4.6 million and a median of $4.6 million in 2018 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods soared 147.88% in 2014 and sank 41.93% in 2015, its largest moves.
• Over 5 years, Finished Goods stood at $3.2 million in 2014, then climbed by 9.3% to $3.5 million in 2015, then grew by 29.64% to $4.5 million in 2016, then rose by 3.02% to $4.7 million in 2017, then decreased by 0.81% to $4.6 million in 2018.
• The last three Finished Goods figures came in at $4.6 million (Q3 2018), $5.2 million (Q2 2018), and $6.8 million (Q1 2018), per Business Quant data.